The role of radiation therapy and chemotherapy in the management of airway tumors other than small-cell carcinoma and non-small-cell carcinoma

Chest Surgery Clinics of North America

Volumn 13, Issue 1, 2003, Pages 149-167

  Kaminski, Joseph M ^a   Langer, Corey J ^a,b   Movsas, Benjamin ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b TEMPLE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; FLUOROURACIL; IFOSFAMIDE; IODINE 125; METHOTREXATE; VINCRISTINE;

ADENOID CYSTIC CARCINOMA; BEAM THERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DYSPHAGIA; HISTOPATHOLOGY; HUMAN; LOBECTOMY; LUNG RESECTION; LUNG TUMOR; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SARCOMA; TRACHEA TUMOR; TREATMENT OUTCOME;

BRONCHIAL NEOPLASMS; CARCINOMA, ADENOID CYSTIC; CARCINOMA, NEUROENDOCRINE; HUMANS; LUNG NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RESPIRATORY TRACT NEOPLASMS; SARCOMA; TRACHEAL NEOPLASMS; TREATMENT OUTCOME;

EID: 0037302658     PISSN: 10523359     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1052-3359(02)00040-6     Document Type: Review

References (113)

1. Ampil FL. Primary malignant tracheal neoplasms: case reports and literature radiotherapy review. J Surg Oncol 1986;33:20-3.
2. American Cancer Society. Cancer facts and figures 2001.
3. Carter D, Eggleston JC. Tumors of the lower respiratory tract. Washington DC: Armed Forces Institute of Pathology; 1980.
4. Houston H, Payne W, Harrison E. Primary cancers of the trachea. Arch Surg 1969;99:132-40.
5. Rosai J. Ackerman's surgical pathology, 6th edition. St. Louis, MO: CV Mosby; 1981.
6. Rostom A, Morgan R. Results of treating primary tumors of the trachea with irradiation. Thorax 1978;33:387-93.
7. World Health Organization. The WHO histologic typing of lung tumors, 2nd edition. Am J Clin Pathol 1982;77:123-36.
8. 111In-DTPA-D-Phe1]-octrotide in patients with neuroendocrine tumors. J Nucl Med 2000;41:1514-8.
9. Krenning EP, Valkema R, Kooij PPM, et al. The role of radioactive somatostatin and its analogues in the control of tumor growth. Recent Results Cancer Res 2000;153:2-13.
10. 111In-Pentetreotide: initial observations and future directions. Cancer J 1998;4:94-102.
11. Wilkins Jr EW, Grillo HC, Moncure AC, et al. Changing times in surgical management of bronchopulmonary carcinoid tumor. Ann Thorac Surg 1984;38:339-44.
12. Carretta A, Ceresoli GL, Arrigoni G, et al. Diagnostic and therapeutic management of neuroendocrine lung tumors: a clinical study of 44 cases. Lung Cancer 2000;20:217-25.
13. Iverson L. Bronchopulmonary sarcoma. J Thorac Surg 1954;27:130-48.
14. McCaughan BC, Martini N, Baines MS. Bronchial carcinoids: review of 124 cases. J Thor Cardiovas Surg 1985;89:8-17.
15. Okike N, Bematz PE, Payne SW, et al. Bronchoplastic procedures in the treatment of carcinoid tumors of the tracheobronchial tree. J Thorac Cardiovasc Surg 1978;76:281-91.
16. Paladugu RR, Benfield JR, Pak HY, et al. Bronchopulmonary Kulchitsky cell carcinomas. Cancer 1985;55:1303-11.
17. Rea F, Binda R, Spreafico G, et al. Bronchial carcinoids: review of 60 patients. Ann Thorac Surg 1989;47:412-4.
18. Warren WH, Faber LP, Gould VE. Neuroendocrine neoplasms of the lung. J Thorac Cardiovasc Surg 1989;98:321-32.
19. Dresler CM, Ritter JH, Patterson A, et al. Clinical-pathologic analysis of 40 patients with large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg 1997;63:180-5.
20. Gould PM, Bonner JA, Sawyer TE, et al. Bronchial carcinoid tumors: importance of prognostic factors that influence patterns of recurrence and overall survival. Radiology 1998;208:181-5.
21. Harpole Jr DH, Feldman JM, Buchanan S, et al. Bronchial carcinoid tumors: a retrospective analysis of 126 patients. Ann Thorac Surg 1992;54:50-4.
22. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998;22:934-44.
23. Davila DG, Dunn WF, Tazelaar HD, et al. Bronchial carcinoid tumors. Mayo Clin Proc 1993;68:795-803.
24. Martini N, Zaman MB, Bains MS, et al. Treatment and prognosis in bronchial carcinoids involving regional lymph nodes. J Thorac Cardiovasc Surg 1994;107:1-7.
25. Thomas Jr CF, Tazelaar HD, Jett JR. Typical and atypical pulmonary carcinoids. Chest 2001;119:1143-50.
26. Grote TH, Macon WR, Davis B, et al. Atypical carcinoid of the lung: a distinct clinical pathologic entity. Chest 1988;93:370-5.
27. Marty-Ane CH, Costes V, Pujol JL, et al. Carcinoid tumors of the lung: do atypical features require aggressive management? Ann Thorac Surg 1995;59:78-83.
28. Moertel CG, Kvols LK, O'Connell MJ, et al. Treatment of neuroendocrine carcinoids combined with etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-32.
29. Hurt R, Bates M. Carcinoid tumors of the bronchus: a 33 year experience. Thorax 1984;39:617-23.
30. Vuitch F, Sekido Y, Fong K, et al. Neuroendocrine tumors of the lung: pathology and molecular biology. Chest Surg Clin N Am 1997;7:21-47.
31. Bernstein C, McGoey J, Lertzman M. Recurrent bronchial carcinoid tumor. Chest 1989;95:693-4.
32. Burcharth F, Axelsson C. Bronchial adenoma. Thorax 1972;27:442-9.
33. Lawson RM, Ramanathan L, Hurley G, et al. Bronchial adenoma: review of an 8 year experience at the Brompton hospital. Thorax 1976;31:245-53.
34. Schupak KD, Wallner KE. The role of radiation therapy in the treatment of locally unresectable or metastatic carcinoid tumors. Int J Radiat Oncol Biol Phys 1991;20:489-95.
35. Moertel CG. An odyssey in the land of small tumors. J Clin Oncol 1987;5:1502-22.
36. Kvols LK, Moertel CG, O'Connell MJ, et al. Treatment of the malignant carcinoid syndrome: evaluation of long-acting somatostatin analog. N Engl J Med 1986;315:663-6.
37. Kvols LK. Therapeutic considerations for malignant carcinoid syndrome. Acta Oncol 1989;28:433-8.
38. Marlink RG, Lokich JJ, Robins JR, et al. Hepatic artery embolization for metastatic hormone secreting tumors. Cancer 1991;65:2227-32.
39. Oberg K, Erickson B. Role of interferon in the management of carcinoid tumors. Acta Oncology 1991;30:519-22.
40. Venook A, Stagg R, Frye J, et al. Chemoembolization of patients with liver metastasis from carcinoid and islet cell tumors. [abstract] Proc Am Soc Clin Oncol 1991;10:130.
41. Moertel CG. Treatment of carcinoid tumor and malignant carcinoid syndrome. J Clin Oncol 1983;1:727-40.
42. Moertel CG, Rubin J, O'Connell MJ. A phase II study of cisplatin therapy in patients with metastatic carcinoid tumor and malignant carcinoid syndrome. Cancer Treat Rep 1986;70:1459-60.
43. Moertel CG, Rubin J, Kvols LK. Therapy of metastatic carcinoid tumor in malignant carcinoid syndrome with recombinant leukocyte alpha interferon. J Clin Oncol 1989;7:865-8.
44. Van Hazel GA, Rubin J, Moertel CG. Treatment of metastatic carcinoid tumor with actinomycin or dacarbazine. Cancer Treat Rep 1983;67:583-5.
45. Kvols LK, Buck M. Chemotherapy of endocrine malignancies: a review. Semin Oncol 1987;14:3343-53.
46. Bukowski RM, Johnson KG, Peterson RF, et al. A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumor. A Southwest Oncology Group Study. Cancer 1987;60:2891-5.
47. Engstrom PF, Levin PT, Folsch E, et al. Streptozotocin plus fluorouracil vs doxorubicin therapy for metastatic carcinoid tumors. J Clin Oncol 1984;2:1255-9.
48. Kelsen DG, Cheng E, Kememy N, et al. Streptozotocin and doxorubicin in the treatment of APUD tumors (carcinoid, islet cell, medullary thyroid). Proc Am Assoc Cancer Res 1982;23:433.
49. Kvols LK, Moertel CG, Schutt AJ, et al. Treatment of malignant carcinoid syndrome with long-acting somatostatin analog: preliminary evidence that more is not better. [abstract] Proc Am Soc Clin Oncol 1987;6:95.
50. Oberg K, Norheim I, Theodorsson E. Treatment of malignant carcinoid tumors with the long-acting somatostatin analog octreotide. Acta Oncol 1991;30:503-7.
51. Al-Saffar N, White A, Moore M, et al. Immunoreactivity of various peptides in typical and atypical bronchial pulmonary carcinoid tumors. Br J Cancer 1988;58:762-6.
52. Rubin JC, Kvols L, Krenning E, et al. In vitro and in vivo detection of somatostatin receptors in human malignant tissues. Acta Oncology 1991;30:463-8.
53. 111In-pentetreotide. State of the art and perspectives. Q J Nucl Med 2000;44:88-95.
54. Mariani G, Bodei L, Adelstein SJ, et al. Emerging roles for radiometabolic therapy of tumors based on auger electron emission. J Nucl Med 2000;41:1519-21.
55. Fjalling M, Andersson P, Forsell-Aronsson E, et al. Systemic radionuclide therapy using [indium-111-DTPA-D-Phe1]-octreotide in midgut carcinoid syndrome. J Nucl Med 1996;37:1517-21.
56. Krenning EP, Kooij PP, Bakker WH, et al. Radiotherapy with a radiolabeled somatostatin analogue [111In-DTPA-D-Phe1]-octreotide: a case history. Ann NY Acad Sci 1994;733:496-506.
57. Krenning EP, Kooij PP, Pauwels S, et al. Somatostatin receptor: scintigraphy and radionuclide therapy. Digestion 1996;57(Suppl 1):57-61.
58. McLean JR, Blakey DH, Douglas GR, et al. The auger electron dosimetry of indium-111 in mammalian cells in vitro. Radiat Res 1989;119:205-18.
59. Taal BG, Hoefnagel CA, Valdes-Olmos RA, et al. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol 1996;14:1829-38.
60. Pearson FG, Todd TRJ, Cooper JD. Experience with primary neoplasms of the trachea and carina. J Thorac Cardiovasc Surg 1984;88:511-6.
61. Belsey R. Resection and reconstruction of intrathoracic trachea. Br J Surg 1950;38:200-5.
62. Grillo HC, Mathison DJ. Primary tracheal tumors: treatment and results. Ann Thorac Surg 1990;49:69-77.
63. Maziak DE, Todd TRJ, Keshavjee SH, et al. Adenoid cystic carcinoma of the airway: thirty-two-year experience. J Thorac Cardiovasc Surg 1996;112:1522-32.
64. Regnard JF, Icard P, Guibert L, et al. Prognostic factors and results after surgical treatment of primary sarcomas of the lung. Ann Thorac Surg 1999;68:227-31.
65. Regnard JF, Fourquier P, Levasseur P. Results and prognostic factors in resections of primary tracheal tumors: a multicenter retrospective study. J Thorac Cardiovasc Surg 1996;111:808-14.
66. Laramore GE, Krall JM, Griffin TW, et al. Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Radiation Therapy Oncology Group. Medical Research Council. Int J Radiat Oncol Biol Phys 1993;27:235-40.
67. Boedker A, Hald A, Kristensen D. A method for selective endobronchial and endotracheal irraditaion. J Thorac Cardiovasc Surg 1982;84:59-61.
68. Percarpio B, Price JC, Murphy P. Endotracheal irradiation of adenoid cystic carcinoma of the trachea. Radiology 1978;128:209-10.
69. Harms W, Latz D, Backer H, et al. HDR-brachytherapy boost for residual tumour after external beam radiotherapy in patients with tracheal malignancies. Radiother Oncol 1999;52:251-5.
70. Manninen M, Pukander JS, Flander MK, et al. Treatment of primary tracheal carcinoma in Finland in 1967-1985. Acta Oncol 1993;32:277-82.
71. Schramm Jr MV, Srodes C, Myers EN. Cisplatin therapy for adenoid cystic carcinoma. Arch Otolarygol 1981;107:739-41.
72. Dimery I, Legha S, Shirinian M, et al. Fluorouracil, doxorubicin, cyclophosphamide and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma. J Clin Oncol 1990;8:1056-62.
73. Dreyfuss A, Clark J, Fallon B, et al. Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinoma of salivary gland origin. Cancer 1987;60:2869-72.
74. Venook A, Tseng Jr A, Myers F. Cisplatin, doxorubicin and 5-fluourouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J Clin Oncol 1987;5:951-5.
75. Cameron EW. Primary sarcoma of the lung. Thorax 1975;30:516-20.
76. Carswell J, Kraeft NH. Fibrosarcoma of the bronchus. J Thorac Surg 1950;19:117-23.
77. Guccion JG, Rosen SH. Bronchopulmonary leiomyosarcoma and fibrosarcoma. A study of 32 cases and review of the literature. Cancer 1972;30:836-46.
78. Martini N, Hadju SI, Beatie Jr EJ. Primary sarcoma of the lung. J Thorac Cardiovasc Surg 1971;61:33-8.
79. Porte HL, Metois DG, Leroy X, et al. Surgical treatment of primary sarcoma of the lung. Eur J Cardiothorac Surg 2000;18:136-42.
80. Bacha EA, Wright CD, Grillo HC, et al. Surgical treatment of primary pulmonary sarcomas. Eur J Cardiothorac Surg 1999;15:456-60.
81. Keel SB, Bacha E, Mark EJ, et al. Primary pulmonary sarcoma: a clinicopathologic study of 26 cases. Mod Pathol 1999;12:1124-31.
82. Lee JT, Shelburne JD, Linder J. Primary malignant fibrous histiocytoma of the lung. A clinicopathologic and ultrastructural study of five cases. Cancer 1984;53:1124-30.
83. Suster SA. Primary sarcomas of the lung. Sem Diagn Pathol 1995;12:140-57.
84. Yousem SA, Hochholzer L. Malignant fibrous histiocytoma of the lung. Cancer 1987;60:2532-41.
85. Aboulafia DM. The epidemiologic, pathologic, and clinical features of AIDS-associated pulmonary Kaposi's sarcoma. Chest 2000;117:1128-45.
86. Antman K, Chang Y. Kaposi's sarcoma. N Engl J Med 2000;342:1027-38.
87. Burt M, Zakowski M. Rare primary malignant neoplasms. In: Griffith F, editor. Thoracic surgery. New York, NY: Churchill Livingstone; 1995. p. 808-26.
88. Santoro A, Ronessé EJ, Steward W, et al. A randomized EORTC study in advanced soft tissue sarcoma, ADM vs ADM + IFX vs Cyvadic. [abstract] Proc Am Soc Clin Oncol 1990;9:309.
89. Antman KH, Ryan L, Elias A, et al. Response to ifosfamide and mesna: 124. Previously treated patients with metasatic or unresectable sarcoma. J Clin Oncol 1989;7:126-31.
90. Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced tissue sarcomas. J Clin Oncol 1993Jul;11(7):1269-75.
91. Turner RR, Colby TV, Doggett RS. Well-differentiated lymphocytic lymphoma: a study of 47 patients with primary manifestations in the lung. Cancer 1984;54:2088-96.
92. Joseph G, Pandit M, Korfhage L. Primary pulmonary plasmacytoma. Cancer 1992;71:721-4.
93. Willis RA. The spread of tumors in the human body. London, UK: Butterworth; 1973.
94. Sisson JC, Giordano TJ, Jamadar DA, et al. 131-I treatment of micronodular pulmonary metastasis from papillary thyroid carcinoma. Cancer 1996;78:2184-2192.
95. Foss FM, Raubitscheck A, Mulshine JL, et al. Phase I study of the pharmokinetics of a radio-immunoconjugate 90-Y-T101, in patients with CD5-expressing leukemia and lymphoma. Clin Cancer Res 1998;4:2691-700.
96. O'Donnell RT, DeNardo GL, Kukis DL, et al. A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma. J Nucl Med 1999;40:2014-20.
97. Weiden PL, Breitz HB, Press O, et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. Cancer Biother Radiopharm 2000;15:15-29.
98. Macha H, Koch K, Stadler M, et al. New techniques for treating occlusive and stenosing tumors of the trachea and main bronchi: endobronchial irradiation by high dose iridium 192 combined with laser canalization. Thorax 1987;42:511-5.
99. Schray M, McDougall J, Martinez A, et al. Management of malignant airway compromise with laser and low dose rate brachytherapy. The Mayo Clinic experience. Chest 1988;93:264-9.
100. Hayman JA, Martel MK, Ten Haken RK, et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol 2001;19:127-36.
101. Attar S, Miller JE, Hankins J, et al. Bronchial adenoma: a review of 51 patients. Ann Thorac Surg 1985;40:126-32.
102. Bertelsen S, Aasted A, Lund C, et al. Bronchial carcinoid tumours. A clinicopathologic study of 82 cases. Scand J Thorac Cardiovasc Surg 1985;19:105-11.
103. Torre M, Barberis M, Barbieri B, et al. Typical and atypical bronchial carcinoids. Respir Med 1989;83:305-8.
104. Stamatis G, Freitag L, Greschuchna D. Limited and radical resection for tracheal and bronchopulmonary carcinoid tumour. Report on 227 cases. Eur J Cardiothorac Surg 1990;4:527-33.
105. Akiba T, Naruke T, Kondo H, et al. Carcinoid tumor of the lung: clinicopathological study of 32 cases. Jpn J Clin Oncol 1992;22:92-5.
106. Chughtai TS, Morin JE, Sheiner NM, et al. Bronchial carcinoid. Twenty years' experience defines a selective surgical approach. Surgery 1997;122:801-8.
107. Vadasz P, Kotsis L, Egervary M, et al. Radicality and prognosis of surgical treatment of thoracal carcinoid tumors: a review of 152 operated cases. Thorac Cardiovasc Surg 1999;47:235-9.
108. Cerfolio RJ, Deschamps C, Allen MS, et al. Mainstem bronchial sleeve resection with pulmonary preservation. Ann Thorac Surg 1996;61:1458-62.
109. Kawahara K, Shiraishi T, Okabayashi K, et al. A new approach for bronchoplastic procedures in the treatment of bronchial carcinoid tumors. Thorac Cardiovasc Surg 1995;43:290-2.
110. Mills SE, Walker AN, Cooper PH, et al. Atypical carcinoids of the lung. Am J Surg Pathol 1982;6:643-54.
111. Rocco G, Deschamps C. Cylindroma, carcinoid tumors, and mucoepidermoid carcinoma. Semin Respir Crit Care Med 1997;18:333-40.
112. Schreurs AJ, Westermann CJ, van den Bosch JM, et al. A twenty-five-year follow-up of ninety-three resected typical carcinoid tumors of the lung. J Thorac Cardiovasc Surg 1992;104:1470-5.
113. 1]-octreotide in patients with neuroendocrine tumors: evaluation of therapeutic and toxic effects. Acta Oncol 1999;38:373-7.